Skip to main content
. 2017 Sep 23;8(55):93825–93838. doi: 10.18632/oncotarget.21225

Figure 2.

Figure 2

(A and B) Metformin and vorinostat showed synergistic apoptosis that was promoted with gefitinib in EGFR-TKI-resistant NSCLC cell-lines. Flow cytometric analysis by Annexin V–FITC/PI staining detected apoptosis induction. Images were representative of three independent experiments. *p < 0.05 as compared with gefitinib treatment alone, #p < 0.05 as compared with gefitinib combined with vorinostat or metformin, Δp < 0.05 as compared with the control (untreated) cells. Gef: gefitinib; SAHA: vorinostat; Met: metformin.